Director, Research & Development Division at Han Wha Pharma Co., Ltd, South Korea.
Dong-Joon Oh is an accomplished R&D leader in the pharmaceutical industry, with deep expertise in formulation development, regulatory affairs, and clinical research strategies. Known for his cross-functional leadership and innovation in drug repositioning and modified-release systems, Mr. Oh has contributed to the development and approval of numerous generic and platform-based products. His strategic insight and successful collaborations with global partners continue to shape advancements in pharmaceutical technology and regulatory excellence. He is currently pursuing a Ph.D. in Pharmacy at Yonsei University while leading R&D initiatives at Han Wha Pharma Co., Ltd.
Publication Profile
Scopus
Education
Mr. Dong-Joon Oh is currently pursuing a Ph.D. in Pharmacy at Yonsei University, South Korea, with an expected completion date in January 2026. He holds a Master of Science degree in Chemical Engineering (2007) and a Bachelor of Science in Nano Life Science and Chemical Engineering (2005), both from Hannam University, Daejeon, South Korea. His educational foundation combines strong interdisciplinary training in pharmaceutical sciences, nanotechnology, and chemical engineering.
Professional Experience
Mr. Dong-Joon Oh is a seasoned pharmaceutical R&D expert with over 15 years of industry experience in drug formulation, regulatory submissions, and technology transfer. He currently serves as a senior researcher at Han Wha Pharma Co., Ltd., where he leads R&D strategy, secures government research grants, and coordinates licensing deals with over 20 pharmaceutical companies. His leadership resulted in the successful execution of 15 R&D projects and the advancement of drug repositioning pipelines.
Prior to this, at Hyundai Pharm Co., Ltd. / Bio-innotis, he managed end-to-end development and submission processes for 12 clinical trial dossiers (IND/CTD), earning recognition as Excellent Researcher (2019) and Best Clinical Submission Awardee (2020). At Celltrion Pharm, Inc., he played a pivotal role as Technical Leader (GGP TL) in developing Celltrion’s first FDA-approved generic drug, overseeing 33 formulation launches and pioneering 5 new platform technologies. His early career at Yungjin Pharmaceutical Co., Ltd. involved formulation development, registration of complex APIs, and new drug development, where he was promoted to Project Leader in 2013.
Research Interest
Mr. Oh’s research focuses on:
-
Pharmaceutical formulation and modified-release technologies
-
Fixed-dose combination (FDC) product development
-
Bioequivalence (BE) and pharmacokinetic (PK) study design
-
Drug repositioning and lifecycle management
-
Regulatory science (IND/CTD preparation for domestic and international markets)
-
Platform R&D and scale-up strategies
-
Technology transfer and translational research in pharmaceutical product commercialization
Author Metrics
-
Years of Experience: 15+ years in pharmaceutical R&D
-
Clinical Dossiers Submitted: 12 IND/CTD submissions
-
Formulations Developed: Over 60, including FDA-approved generics
-
Technology Transfers & Licenses: 8 products transferred to 20+ partners
-
Recognition:
-
Excellent Researcher (2019, Hyundai Pharm)
-
Best Clinical Submission Award (2020, Bio-innotis)
Top Noted Publication
Solubility of Simvastatin and Lovastatin in Mixtures of Dichloromethane and Supercritical Carbon Dioxide
authored by Dong-Joon Oh, Byung-Chul Lee, and Sung-Joo Hwang
published in the Journal of Chemical & Engineering
Year: 2007
Citation: 19
Conclusion
Mr. Dong-Joon Oh is highly suitable for the Best Researcher Award in Pharmaceutical Formulation, particularly in the context of industry-driven innovation, technology transfer, and regulatory excellence. His hands-on achievements in developing 60+ formulations, leading major R&D programs, and achieving global approvals reflect leadership, depth, and impact in pharmaceutical sciences.
To further solidify his candidacy, it is recommended he amplify his academic publication output, increase global scientific engagement, and strengthen innovation visibility through patents or novel technologies. Nonetheless, his profile already places him among top-tier industry researchers with transformative contributions to drug development and commercialization.